Key facts
- Notable investors include Peiyang Begonia Fund.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Tianjin Kedao Boji Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Tianjin Kedao Boji Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tianjin Kedao Boji Biotechnology
Developer of advanced biotechnology products designed to support health and life sciences research and innovation. The company offers cutting-edge immunohistochemical antibody reagents, pathological staining reagents, and in vitro diagnostic reagents alongside supporting instruments, enabling scientific researchers and pharmaceutical developers to accelerate discovery and enhance diagnostic precision.
- Sector
- Healthcare
- HQ
- Tianjin, China
- Founded
- 2024
- Ownership
- Privately Held (backing)
Tianjin Kedao Boji Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tianjin Kedao Boji Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tianjin Kedao Boji Biotechnology in its N-PORT filings yet. We sweep new filings monthly.